A 28-year-old woman with genetic hair loss has tried various treatments, including oral minoxidil, finasteride, dutasteride, vitamins, ketoconazole shampoo, exosome needling, and hair extensions. She plans to pause treatments for pregnancy and is concerned about potential hair loss during that time.
The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.
The conversation is about hair regrowth treatments, including ketoconazole, vitamins, fish oil, collagen, pumpkin seed oil, rosemary, and dermal rolling. Users suggest trying finasteride and intense weight training to enhance results.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
The user is experiencing hair loss with possible causes including chronic telogen effluvium, diffuse alopecia areata, and androgenic alopecia. They have tried treatments like Nizoral shampoo, minoxidil, and finasteride, and are considering a biopsy for further clarity.
Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.
The user experienced hair thinning on TRT and considered various treatments suggested by an online clinic, including GHK-Cu Scalp Serum and Minoxidil blends. The consensus is that only finasteride or dutasteride effectively stop hair loss, while Minoxidil can thicken hair.
A 22-year-old male with high estrogen levels is considering finasteride for hair loss but is concerned about potential side effects due to his hormone levels and family history of diabetes. Users suggest consulting a doctor, possibly an endocrinologist, and considering lifestyle changes like diet and exercise to address visceral fat and insulin resistance before starting treatment.
The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.
User experienced side effects from oral finasteride and tried topical Alfatradiol for hair loss. Alfatradiol provided maintenance without significant regrowth, and user suggests it as an alternative for those struggling with finasteride side effects.
He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.
A 25-year-old discusses using castor oil combined with minoxidil for alopecia areata after noticing hair loss. They seek advice on the effectiveness of this treatment.
User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hair follicles for better treatment.
A 34-year-old woman is experiencing diffuse hair loss and irregular periods, possibly due to long-term spironolactone use. She is considering minoxidil and finasteride for treatment and seeking medical advice for androgenic alopecia and hormonal imbalances.
A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.
A 29 year old female with hair loss issues that have been linked to PCOS; the user has started taking Spironolactone and iron supplements in hopes of regrowing their hair, but is wondering if it's too late.
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
A 20-year-old saw significant hair regrowth after 9 months of using DHT blockers (finasteride and dutasteride) and 6 months of hormone replacement therapy (HRT) with estradiol. The regrowth is attributed to low testosterone and high estradiol levels, without using Minoxidil.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.
Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.
The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.